Compare
Kesimpta vs. Gilenya

Kesimpta (ofatumumab) is an injectable medication for adults with relapsing forms of multiple sclerosis (MS). It works as a monoclonal antibody to help lessen MS flare-ups that come and go. Kesimpta (ofatumumab) is injected under the skin. You can use the Kesimpta prefilled syringes or Sensoready Pens to inject. After the first 3 weekly injections, you inject the medication once a month. Some common side effects include a higher risk of infections, pain or swelling at the injection site, and headache.

• Relapsing forms of multiple sclerosis (MS), including relapsing-remitting MS, clinically isolated syndrome, and secondary progressive MS

• Upper respiratory tract infections (39%)
• Reactions related to the injection (e.g., fever, chills, tiredness; 21%)
• Headache (13%)
• Reaction at the injection site (e.g., pain, redness, swelling; 11%)
• Urinary tract infection (10%)

• Risk of infections
• Injection reactions
• Lower antibody levels
• Harm to an unborn baby

Fingolimod (Gilenya) is a disease-modifying treatment option for relapsing multiple sclerosis (MS). It works well to lower the number of MS relapses. Fingolimod (Gilenya) is taken by mouth, typically once daily, and can be used by adults and children age 10 years and older. But fingolimod (Gilenya) can cause potentially serious side effects, such as a higher risk for infections and heart problems, so it's not the best choice for everyone.

• Relapsing forms of multiple sclerosis (MS)

• Headache (25%)
• High liver enyzmes (15%)
• Nausea (13%)
• Diarrhea (13%)
• Cough (12%)
• Stomach pain (11%)
• Influenza (11%)
• Sinus inflammation (11%)
• Pain in back (10%)
• Pain in arms or legs (10%)

• Dangerously slow heart rate
• Serious infections
• Progressive multifocal leukoencephalopathy (PML)
• Eye problems
• Liver damage
• Breathing problems
• Harm to unborn babies
• Risk of cancer
• Brain problems